Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Finapark is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. Finapark has not been shown to be effective as monotherapy for the treatment of Parkinson's disease.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
For Usual Initial Dosage: The recommended starting dosage of Safinamide tablet is 50 mg orally once daily (at the same time of day). If a dose is missed, the next dose should be taken at the same time the next day.For Maintenance dosage: After 2 weeks, the dose may be increased to 100 mg once daily, based on individual need and tolerability. Safinamide 100 mg should be tapered by decreasing the dose to 50 mg for one week before stopping.Use in Children: Safety & effectiveness of Safinamide in infants & children have not been established.Geriatric Use: No overall differences in safety or effectiveness were observed in these patients and younger patients.Hepatic Impairment: Safinamide plasma concentrations are increased in patients with hepatic impairment.
Side Effects
Most common adverse reactions of Finapark’s are dyskinesia, fall, nausea, and insomnia.
Cautions & Contraindications
Warnings & Precautions
May cause or exacerbate hypertension May cause serotonin syndrome when used with MAO inhibitors, antidepressants, or opioid drugs May cause falling asleep during activities of daily living May cause or exacerbate dyskinesia; consider levodopa dose reduction May cause hallucinations and psychotic behavior May cause problems with impulse control/compulsive behaviors May cause withdrawal-emergent hyperpyrexia and confusion
Contraindications
Safinamide is contraindicated in patients with:Concomitant use of the following drugs: Other monoamine oxidase inhibitors or other drugs that are potent inhibitors of monoamine oxidase (e.g., linezolid) Opioid drugs (e.g., tramadol, meperidine and related derivatives); selective norepinephrine reuptake inhibitors; tri-or tetra-cyclic or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; St. John’s wort Dextromethorphan A history of a hypersensitivity to safinamideSevere hepatic impairment (Child-Pugh C: 10-15)